Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed or Refactory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Next Previous
Trial Profile

A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed or Refactory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; AT 101
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 11 Jun 2020 Status changed from active, no longer recruiting to discontinued.
  • 11 Jun 2020 Status changed from active, no longer recruiting to discontinued.
  • 17 Dec 2018 Status changed from suspended to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top